Sign In  |  Register  |  About Livermore  |  Contact Us

Livermore, CA
September 01, 2020 1:25pm
7-Day Forecast | Traffic

  • Search Hotels in Livermore

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by ReAlta Life Sciences, Inc.

ReAlta Life Sciences Announces Appointment of Distinguished Biopharmaceutical Leader Lewis T. “Rusty” Williams, M.D., Ph.D. as Chairman of the Board
From ReAlta Life Sciences, Inc.
Via Business Wire
ReAlta Life Sciences Announces Presentation of RLS-0071 (pegtarazimod) Data in aGVHD at American Society of Hematology Annual Meeting
From ReAlta Life Sciences, Inc.
Via Business Wire
ReAlta Life Sciences Announces First Patient Dosed in Phase 2 Study Evaluating RLS-0071 for the Treatment of Steroid-Refractory Acute Graft-versus-Host Disease
From ReAlta Life Sciences, Inc.
Via Business Wire
ReAlta Life Sciences Further Bolsters Experienced Executive Team with the Appointment of Peter Ho, Ph.D., as Head of Business Development and Corporate Strategy
From ReAlta Life Sciences, Inc.
Via Business Wire
ReAlta Life Sciences Invigorates Executive Team with Appointments of David Marek as Chief Executive Officer and Paolo Martini, Ph.D., as Chief Research and Development Officer
From ReAlta Life Sciences, Inc.
Via Business Wire
ReAlta Life Sciences Announces New Research Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate RLS-0071 as a Medical Countermeasure for Acute Radiation Syndrome
From ReAlta Life Sciences, Inc.
Via Business Wire
ReAlta Life Sciences Announces Dosing of First Patient in Phase 2 Trial of RLS-0071 for Acute Exacerbations of Chronic Obstructive Pulmonary Disease
From ReAlta Life Sciences, Inc.
Via Business Wire
ReAlta Life Sciences Strengthens Board of Directors with Appointment of Two Accomplished Biotechnology Innovators
From ReAlta Life Sciences, Inc.
Via Business Wire
ReAlta Life Sciences Strengthens Board of Directors with Appointment of Three Accomplished Biotechnology Executives
From ReAlta Life Sciences, Inc.
Via Business Wire
ReAlta Life Sciences Receives FDA Clearance for Phase 2 Trial of RLS-0071 in Patients with Acute Exacerbations of Chronic Obstructive Pulmonary Disease
From ReAlta Life Sciences, Inc.
Via Business Wire
Senator Mark Warner Visits ReAlta Life Sciences’ Biotech Research Facility, Highlights Importance of Rare Disease Innovation
From ReAlta Life Sciences, Inc.
Via Business Wire
ReAlta Life Sciences Receives FDA Clearance for Phase 2 Trial of RLS-0071 in Hospitalized Patients with Steroid-Refractory Acute Graft-Versus-Host Disease
From ReAlta Life Sciences, Inc.
Via Business Wire
ReAlta Life Sciences Announces Poster Presentation at the European Respiratory Society 2023 International Congress
From ReAlta Life Sciences, Inc.
Via Business Wire
ReAlta Life Sciences Doses First Patient in Phase 2 STAR-Study of RLS-0071 for Hypoxic Ischemic Encephalopathy in Newborns
From ReAlta Life Sciences, Inc.
Via Business Wire
Congressman Bobby Scott Tours ReAlta Life Sciences’ Biotech Research Facility, Highlights Importance of Rare Disease Innovation
From ReAlta Life Sciences, Inc.
Via Business Wire
ReAlta Life Sciences Announces Poster Presentation at the American Thoracic Society 2023 Annual Meeting
From ReAlta Life Sciences, Inc.
Via Business Wire
USA FDA Grants Fast Track Designation to ReAlta Life Sciences’ Lead Compound RLS-0071 for the Treatment of Hypoxic-Ischemic Encephalopathy In Neonates
From ReAlta Life Sciences, Inc.
Via Business Wire
ReAlta Life Sciences, Inc. Doses First Patient in Phase 1b Inhaled-LPS Challenge Clinical Trial to Support Development of RLS-0071 in Severe Asthma
From ReAlta Life Sciences, Inc.
Via Business Wire
Germany’s BfArM Approves ReAlta Life Science’s Phase 1b Inhaled LPS Challenge Trial to Support Development of RLS-0071 in Severe Asthma
From ReAlta Life Sciences, Inc.
Via Business Wire
ReAlta Life Sciences Receives $3.2 Million Grant from Virginia Catalyst to Accelerate Trial for the Treatment of Acute Lung Injury Due to COVID-19
From ReAlta Life Sciences, Inc.
Via Business Wire
ReAlta Life Sciences Closes $20 Million Series A3 Financing to Advance Multiple Programs into Phase 2 Clinical Trials
From ReAlta Life Sciences, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Livermore.com & California Media Partners, LLC. All rights reserved.